NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|124|3|537-545

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.3, 2018-02, pp. : 537-545

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 117-121

Karger

Access to resources Recommend Favorite

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2253-2261

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 2961-2970

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1654-1661

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2016-2024

John Wiley & Sons Inc

Access to resources Recommend Favorite